A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
{{output}}
Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeuti... ...
